Cargando…

Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy

BACKGROUND: Inhibition of the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) axis in combination with radiotherapy may be a promising approach to treat cancer. In the present study, we aimed to evaluate serum soluble PD-1/PD-L1 levels in patients with advanced rectal cancer trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tominaga, Tetsuro, Akiyoshi, Takashi, Yamamoto, Noriko, Taguchi, Senzo, Mori, Seiichi, Nagasaki, Toshiya, Fukunaga, Yosuke, Ueno, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390997/ https://www.ncbi.nlm.nih.gov/pubmed/30807610 http://dx.doi.org/10.1371/journal.pone.0212978

Ejemplares similares

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Transcriptomic Analyses of Pretreatment Tumor Biopsy Samples, Response to Neoadjuvant Chemoradiotherapy, and Survival in Patients With Advanced Rectal Cancer
por: Akiyoshi, Takashi, et al.
Publicado: (2023)

Skeletal muscle loss is an independent negative prognostic factor in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy
por: Takeda, Yasuhiro, et al.
Publicado: (2018)

Serum miR-143 levels predict the pathological response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
por: Hiyoshi, Yukiharu, et al.
Publicado: (2017)

Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial)
por: Akiyoshi, Takashi, et al.
Publicado: (2022)

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
por: Chang, Boyang, et al.
Publicado: (2018)

The predictive role of soluble programmed death ligand 1 in digestive system cancers
por: Ruan, Jian, et al.
Publicado: (2023)

Senescent cells re‐engineered to express soluble programmed death receptor‐1 for inhibiting programmed death receptor‐1/programmed death ligand‐1 as a vaccination approach against breast cancer
por: Chen, Zehong, et al.
Publicado: (2018)

Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C
por: Yamagiwa, Satoshi, et al.
Publicado: (2017)

Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer
por: Molga-Magusiak, Maria, et al.
Publicado: (2023)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
por: Liu, Shujun, et al.
Publicado: (2020)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma
por: Lu, Tianzhu, et al.
Publicado: (2020)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
por: Huang, Pei, et al.
Publicado: (2021)

Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells
por: Liang, Zhaoduan, et al.
Publicado: (2023)

A case of severe megacolon due to acquired isolated hypoganglionosis after low anterior resection for lower rectal cancer
por: Tominaga, Tetsuro, et al.
Publicado: (2019)

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas
por: Liu, Shujun, et al.
Publicado: (2020)

Soluble programmed death‐1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B
por: Zhou, Liang, et al.
Publicado: (2019)

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T‐cell lymphomas
por: Zhang, Xuhan, et al.
Publicado: (2019)

Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment
por: Kozuka, Ritsuzo, et al.
Publicado: (2022)

Soluble programmed death molecule 1 (sPD-1) as a predictor of interstitial lung disease in rheumatoid arthritis
por: Xu, Li, et al.
Publicado: (2021)

The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer
por: Shao, Weifang, et al.
Publicado: (2022)

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
por: Guo, Xiaofang, et al.
Publicado: (2018)

Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis
por: Wei, Wei, et al.
Publicado: (2018)

Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer
por: Park, Hyunkyung, et al.
Publicado: (2019)

Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome
por: Li, Shuping, et al.
Publicado: (2022)

Clinical significance of soluble programmed cell death‐ligand 1 in hepatitis B virus‐related hepatocellular carcinoma
por: Yang, Zhongxia, et al.
Publicado: (2023)

Neoadjuvant Chemoradiotherapy Changes the Landscape of Soluble Immune Checkpoint Molecules in Patients With Locally Advanced Rectal Cancer
por: Liu, Chao, et al.
Publicado: (2022)

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
por: Christiansson, Lisa, et al.
Publicado: (2013)

Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer
por: Akiyoshi, T., et al.
Publicado: (2019)

Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
por: Bailly, Christian, et al.
Publicado: (2021)

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
por: Wang, Liang, et al.
Publicado: (2015)

The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes
por: Ding, Xing-Chen, et al.
Publicado: (2020)

Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
por: Park, Woochan, et al.
Publicado: (2021)

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy
por: Tanizaki, Junko, et al.
Publicado: (2023)

Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men
por: Katongole, Paul, et al.
Publicado: (2022)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2022)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Difficulty of predicting lymph node metastasis on CT in patients with rectal neuroendocrine tumors
por: Ushigome, Hajime, et al.
Publicado: (2019)

The relationship between the expression of soluble programmed cell death-1 and cancer pain: A protocol for systematic review and meta analysis
por: Zhu, Guangfeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ovi057k78m8vg77b53q77d4fh0